Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 13832/0091.
Xgeva PFS
XGEVA 120 mg solution for injection in pre-filled syringe
denosumab
1. What XGEVA is and what it is used for
2. What you need to know before you use XGEVA
3. How to use XGEVA
4. Possible side effects
5. How to store XGEVA
6. Contents of the pack and other information
XGEVA contains denosumab, a protein (monoclonal antibody) that works to slow down bone destruction caused by cancer spreading to the bone (bone metastasis) or by giant cell tumour of bone.
XGEVA is used in adults with advanced cancer to prevent serious complications caused by bone metastasis (e.g. fracture, pressure on the spinal cord or the need to receive radiation therapy or surgery).
XGEVA is also used to treat giant cell tumour of bone, which cannot be treated by surgery or where surgery is not the best option, in adults and adolescents whose bones have stopped growing.
Your healthcare professional will not administer XGEVA to you if you have a very low level of calcium in your blood which has not been treated.
Your healthcare professional will not administer XGEVA to you if you have unhealed wounds from dental or oral surgery.
Talk to your doctor before using XGEVA.
Calcium and vitamin D supplementation
You should take calcium and vitamin D supplements while being treated with XGEVA unless your blood calcium is high. Your doctor will discuss this with you. If the level of calcium in your blood is low, your doctor may decide to give you calcium supplements before you start treatment with XGEVA.
Low calcium levels in the blood
Please tell your doctor immediately if you have spasms, twitches, or cramps in your muscles, and/or numbness or tingling in your fingers, toes or around your mouth and/or seizures, confusion or loss of consciousness while being treated with XGEVA. You may have low levels of calcium in your blood.
Renal impairment
Tell your doctor if you have or have had severe kidney problems, kidney failure or have needed dialysis, which may increase your risk of getting low blood calcium, especially if you do not take calcium supplements.
Problems with your mouth, teeth or jaw
A side effect called osteonecrosis of the jaw (bone damage in the jaw) has been reported commonly (may affect up to 1 in 10 people) in patients receiving XGEVA injections for cancer-related conditions. Osteonecrosis of the jaw can also occur after stopping treatment.
It is important to try to prevent osteonecrosis of the jaw developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take:
Patients undergoing chemotherapy and/or radiotherapy, taking steroids or anti-angiogenic medicines (used to treat cancer), undergoing dental surgery, who do not receive routine dental care, have gum disease or who are smokers, may have a higher risk of developing osteonecrosis of the jaw.
Unusual thigh bone fractures
Some people have developed unusual fractures in their thigh bone while being treated with XGEVA. Contact your doctor if you experience new or unusual pain in your hip, groin, or thigh.
High calcium levels in the blood after stopping treatment with XGEVA
Some patients with giant cell tumour of the bone have developed high calcium levels in the blood weeks to months after stopping treatment. Your doctor will monitor you for signs and symptoms of high levels of calcium, after you stop receiving XGEVA.
XGEVA is not recommended for children and adolescents under 18 years of age except for adolescents with giant cell tumour of the bone whose bones have stopped growing. The use of XGEVA has not been studied in children and adolescents with other cancers that have spread to bone.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription. It is especially important that you tell your doctor if you are being treated with
You should not take XGEVA together with other medicines containing denosumab or bisphosphonates.
XGEVA has not been tested in pregnant women. It is important to tell your doctor if you are pregnant, think you may be pregnant, or plan to get pregnant. XGEVA is not recommended for use if you are pregnant. Women of child-bearing potential should use effective methods of contraception while being treated with XGEVA and for at least 5 months after stopping treatment with XGEVA.
If you become pregnant during treatment with XGEVA or less than 5 months after stopping treatment with XGEVA, please inform your doctor.
It is not known whether XGEVA is excreted in breast milk. It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding or whether to stop taking XGEVA, considering the benefit of breast-feeding to the baby and the benefit of XGEVA to the mother.
If you are nursing during treatment with XGEVA, please inform your doctor.
Ask your doctor or pharmacist for advice before taking any medicine.
XGEVA has no or negligible influence on the ability to drive and use machines.
This medicine contains 37 mg sorbitol in each pre-filled syringe.
This medicine contains less than 1 mmol sodium (23 mg) per 120 mg dose, that is to say essentially ‘sodium-free’.
This medicine contains 6.1 mg of phenylalanine in each pre-filled syringe.
Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
For instructions on how to inject XGEVA, please read the section at the end of this leaflet.
The recommended dose of XGEVA is 120 mg administered once every 4 weeks, as a single injection under the skin (subcutaneous). You can inject the XGEVA pre-filled syringe in your thigh or belly (except 5 cm (2 inches) around your belly button). The first self-administration with the XGEVA pre-filled syringe should be supervised by a healthcare professional. If someone else gives you the injection, XGEVA can be injected into your thigh, belly, or outer area of the upper arm. You or your caregiver should be trained in injection techniques by a healthcare professional. If you are being treated for giant cell tumour of bone, you will receive an additional dose 1 week and 2 weeks after the first dose.
Do not shake.
You should also take calcium and vitamin D supplements while being treated with XGEVA unless you have an excess of calcium in the blood. Your doctor will discuss this with you.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Please tell your doctor immediately if you develop any of these symptoms while being treated with XGEVA (may affect more than 1 in 10 people):
Please tell your doctor and dentist immediately if you experience any of these symptoms while being treated with XGEVA or after stopping treatment (may affect up to 1 in 10 people):
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
or search for MHRA Yellow Card in the Google Play or Apple App Store
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C – 8°C).
Do not freeze.
Keep the pre-filled syringe in the outer carton in order to protect from light.
The pre-filled syringe may be left outside the refrigerator to reach room temperature (up to 25°C) before injection. This will make the injection more comfortable. Once the pre-filled syringe has been left to reach room temperature (up to 25°C), do not put it back in the refrigerator and it must be used within 30 days.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
XGEVA is a solution for injection (injection).
XGEVA is a clear, colourless to slightly yellow solution. It may contain trace amounts of translucent to white proteinaceous particles.
Each pack contains one, three or four single use pre-filled syringes with needle guards.
Not all pack sizes may be marketed.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in February 2024.
Getting to know your pre-filled syringe with Automatic Needle Guard
Using your XGEVA pre-filled syringe:
Important: Keep the pre-filled syringe and sharps disposal container out of the sight and reach of children.
2a Grasp the pre-filled syringe by the barrel and remove from the tray.
2b Wait 30 minutes for the pre-filled syringe to reach room temperature.
WAIT 30 minutes
2c Gather and place the items for your injection on a clean, well-lit surface.
3a Inspect the medicine.
Medicine
Important: If the medicine is cloudy, discoloured, or has particles, call your doctor or healthcare provider.
3b Check the expiry date (EXP) and inspect the pre-filled syringe.
Expiry date
Important: In all cases, call your doctor or healthcare provider.
3c Inject in one of these locations.
Important: Avoid areas with scars, stretch marks, or where skin is tender, bruised, red or hard.
Important: Only remove the needle cap when you can inject right away (within 5 minutes) as this can dry out the medicine.
4a Pull the needle cap straight off while holding the pre-filled syringe barrel.
4b Pinch the skin around the injection site before the injection.
PINCH
4c Insert the needle into the pinched skin.
INSERT
4d Slowly press the plunger head down until it is completely between the needle guard clips. You may feel or hear a “snap”.
INJECT
4e Keep pressure on the plunger head and remove the needle from skin.
LIFT
Important: Never put the needle cap back on.
5a Discard the used pre-filled syringe and needle cap in the sharps disposal container.
Do not recycle the pre-filled syringe or throw it into the household waste.